Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Apollo Global Management Ord Shs (APO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Apollo Global Management Ord Shs — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.12 (market cap $29.60B), while Apollo Global Management Ord Shs trades at $139.38 (market cap $82.84B). The key difference: Apollo Global Management Ord Shs is far larger — about 2.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Apollo Global Management Ord Shs pays a 1.6% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | APO | |
|---|---|---|
Market Cap | $29.60B | $82.84B |
Sector | Health | Financials |
52-Week High | $491.22 | $152.70 |
52-Week Low | $205.48 | $100.30 |
Enterprise Value | $27.56B | -$168.65B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Apollo Global Management (APO) trades at $137.75, up 4.34% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Q2 2026 earnings missed estimates at $2.11 per share versus $2.16 expected, but revenue growth remains robust with record fee-related earnings. Recent news highlights strategic AI infrastructure deals and a $2.6 billion financing agreement with Yankee Global Enterprises.
Outlook is positive with an 82% analyst buy rating and $151.50 consensus price target, implying 10% upside. Risks include expense growth impacting net margins and competitive pressures in asset management. The company's strong capital formation and perpetual capital base support long-term growth, but investors should monitor execution on AI initiatives and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →
